Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP263548.RAcqjSlsEnqCSWG1vU-uNE0KmQwcSYzfGX3pxCyiKFV8I130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP263548.RAcqjSlsEnqCSWG1vU-uNE0KmQwcSYzfGX3pxCyiKFV8I130_provenance.
• NP669429.RAAam-DIbPOpx66g44bYIwMhSjJWfD6Qk_Dyt8vGUpcks130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP669429.RAAam-DIbPOpx66g44bYIwMhSjJWfD6Qk_Dyt8vGUpcks130_provenance.
• NP774584.RABv5zvtoN-yIPRTltXeZqWHifD5bNNoDNAR3g1ea93y8130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP774584.RABv5zvtoN-yIPRTltXeZqWHifD5bNNoDNAR3g1ea93y8130_provenance.
• NP281792.RAOgLbfdjc2MskEx3bYZc5ytP66TPgH6JrT4mBxyEZ1Sc130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP281792.RAOgLbfdjc2MskEx3bYZc5ytP66TPgH6JrT4mBxyEZ1Sc130_provenance.
• NP474334.RAKZ81AmZ6TNLNBOAnHQRTJPvYINc3CUfG1YKEPfdatRU130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP474334.RAKZ81AmZ6TNLNBOAnHQRTJPvYINc3CUfG1YKEPfdatRU130_provenance.
• assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP499323.RAaOtEDhescfyyLK_T57-RfwhNXKkD1xmswpBkPAUixCs130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499323.RAaOtEDhescfyyLK_T57-RfwhNXKkD1xmswpBkPAUixCs130_provenance.
• NP557409.RAAP-IE8qnDCyDuT5LRmvtFW_EgYc1zj7qpL1tg1X5Otw130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557409.RAAP-IE8qnDCyDuT5LRmvtFW_EgYc1zj7qpL1tg1X5Otw130_provenance.
• NP681837.RArebDI5J_IxiggaaFgypNC0R2vP1reGn8spD11IeUPp0130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP681837.RArebDI5J_IxiggaaFgypNC0R2vP1reGn8spD11IeUPp0130_provenance.
• NP499326.RAlEepRXFkFJxf_cUgJ5CpPQXo7jqaOYS9X8E0sEkbbK0130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499326.RAlEepRXFkFJxf_cUgJ5CpPQXo7jqaOYS9X8E0sEkbbK0130_provenance.
• NP541740.RAG5s1dfbTzeUfBrrHMCpuKsAWUKeE5vEcEsEPuYVai48130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP541740.RAG5s1dfbTzeUfBrrHMCpuKsAWUKeE5vEcEsEPuYVai48130_provenance.
• NP541682.RA917NlF5ZGXyjdSQLt_HPzkuRbD7nuKxeFsYm0K-etAw130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP541682.RA917NlF5ZGXyjdSQLt_HPzkuRbD7nuKxeFsYm0K-etAw130_provenance.
• NP681768.RAGgdkuZn8aCNHAu9X1hFN-N9uIWCUcozIsiTtQ7-qVmw130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP681768.RAGgdkuZn8aCNHAu9X1hFN-N9uIWCUcozIsiTtQ7-qVmw130_provenance.
• NP499322.RAGs5xB0lIXnZ19e-osfUoEZ4B3RWnpWr5MpLwuqLMQbc130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499322.RAGs5xB0lIXnZ19e-osfUoEZ4B3RWnpWr5MpLwuqLMQbc130_provenance.
• NP499324.RA7IVnb-nHSW5SmboogLtl-C4zc5QBglCcVtpmNsGpaLM130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499324.RA7IVnb-nHSW5SmboogLtl-C4zc5QBglCcVtpmNsGpaLM130_provenance.
• NP499325.RAyKnWeAG0rWSFoGIaYNTLZzE22U6o0cI8NGbCMvdsZDo130_assertion description "[We suggest that SCA6, in common with SCA2 and SCA3, may be associated with Parkinsonism attributable to nigral loss and dopaminergic dysfunction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499325.RAyKnWeAG0rWSFoGIaYNTLZzE22U6o0cI8NGbCMvdsZDo130_provenance.